Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 619-627

  Davies, John Q ^a,g   Lin, Hsi Hsien ^b   Stacey, Martin ^c   Yona, Simon ^a   Chang, Gin Wen ^b   Gordon, Siamon ^a   Hamann, Jörg ^d   Campo, Leticia ^e   Han, Cheng ^e   Chan, Peter ^f   Fox, Stephen B ^e,f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Adhesion GPCR; Breast cancer; EMR2; Nucleus; Survival

Indexed keywords

BIOLOGICAL MARKER; CD97 ANTIGEN; EPIDERMAL GROWTH FACTOR LIKE MODULE CONTAINING MUCIN LIKE HORMONE; G PROTEIN COUPLED RECEPTOR; GENOMIC DNA; RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE ADHERENCE; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTORS, G-PROTEIN-COUPLED; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551592761     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1117     Document Type: Article

References (32)

1. Yona S, Lin HH, Siu WO, Gordon S and Stacey M: Adhesion-GPCRs: emerging roles for novel receptors. Trends Biochem Sci 33: 491-500, 2008.
2. Leemans JC, te Velde AA, Florquin S, et al: The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense. J Immunol 172: 1125-1131, 2004.
3. Lin HH, Faunce DE, Stacey M, et al: The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J Exp Med 201: 1615-1625, 2005.
4. Yona S, Lin HH, Dri P, et al: Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function. FASEB J 22: 741-751, 2008.
5. + T cells mediated by CD97. J Immunol 177: 1070-1077, 2006.
6. Wang T, Ward Y, Tian L, et al: CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 105: 2836-2844, 2005.
7. Jaspars LH, Vos W, Aust G, Van Lier RA and Hamann J: Tissue distribution of the human CD97 EGF-TM7 receptor. Tissue Antigens 57: 325-331, 2001.
8. Aust G, Eichler W, Laue S, et al: CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 57: 1798-1806, 1997.
9. Aust G, Steinert M, Schutz A, et al: CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am J Clin Pathol 118: 699-707, 2002.
10. Mustafa T, Klonisch T, Hombach-Klonisch S, et al: Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int J Oncol 24: 285-294, 2004.
11. Galle J, Sittig D, Hanisch I, et al: Individual cell-based models of tumor-environment interactions: Multiple effects of CD97 on tumor invasion. Am J Pathol 169: 1802-1811, 2006.
12. Steinert M, Wobus M, Boltze C, et al: Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol 161: 1657-1667, 2002.
13. Lin HH, Stacey M, Hamann J, Gordon S and McKnight AJ: Human EMR2, a novel EGF-TM7 molecule on chromosome 19p13.1, is closely related to CD97. Genomics 67: 188-200, 2000.
14. Kwakkenbos MJ, Pouwels W, Matmati M, et al: Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J Leukoc Biol 77: 112-119, 2005.
15. Stacey M, Chang GW, Davies JQ, et al: The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood 102: 2916-2924, 2003.
16. Campo L, Turley H, Han C, et al: Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. J Pathol 205: 585-591, 2005.
17. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004.
18. Chang GW, Stacey M, Kwakkenbos MJ, Hamann J, Gordon S and Lin HH: Proteolytic cleavage of the EMR2 receptor requires both the extracellular stalk and the GPS motif. FEBS Lett 547: 145-150, 2003.
19. Tan EY, Campo L, Han C, et al: BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin Cancer Res 13: 467-474, 2007.
20. Dhanasekaran N, Heasley LE and Johnson GL: G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev 16: 259-270, 1995.
21. Muller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001.
22. Suwiwat S, Ricciardelli C, Tammi R, et al: Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 10: 2491-2498, 2004.
23. Gobeil F, Fortier A, Zhu T, et al: G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol 84: 287-297, 2006.
24. Re R: The nature of intracrine peptide hormone action. Hypertension 34: 534-538, 1999.
25. Watson PH, Fraher LJ, Natale BV, Kisiel M, Hendy GN and Hodsman AB: Nuclear localization of the type 1 parathyroid hormone/parathyroid hormone-related peptide receptor in MC3T3-E1 cells: association with serum-induced cell proliferation. Bone 26: 221-225, 2000.
26. Shibuta K, Mori M, Shimoda K, Inoue H, Mitra P and Barnard GF: Regional expression of CXCL12/CXCR4 in liver and hepatocellular carcinoma and cell-cycle variation during in vitro differentiation. Jpn J Cancer Res 93: 789-797, 2002.
27. Spano JP, Andre F, Morat L, et al: Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 15: 613-617, 2004.
28. Nielsen CK, Campbell JI, Ohd JF, et al: A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res 65: 732-742, 2005.
29. Wang N, Wu QL, Fang Y, et al: Expression of chemokine receptor CXCR4 in nasopharyngeal carcinoma: pattern of expression and correlation with clinical outcome. J Transl Med 3: 26, 2005.
30. Lee DK, Lanca AJ, Cheng R, et al: Agonist-independent nuclear localization of the Apelin, angiotensin AT1, and bradykinin B2 receptors. J Biol Chem 279: 7901-7908, 2004.
31. Christophe D, Christophe-Hobertus C and Pichon B: Nuclear targeting of proteins: how many different signals? Cell Signal 12: 337-341, 2000.
32. van der Bij GJ, Oosterling SJ, Meijer S, Beelen RH and van Egmond M: The role of macrophages in tumor development. Cell Oncol 27: 203-213, 2005.